



## **MannKind Corporation to Hold Investor Conference Call**

December 27, 2018

**- Scheduled for Friday, January 4, 2019 at 9 AM ET -**

WESTLAKE VILLAGE, Calif., Dec. 27, 2018 (GLOBE NEWSWIRE) -- **MannKind Corporation (NASDAQ: MNKD)** will host a conference call on Friday, January 4, 2019 to discuss Company developments at 9:00 AM (Eastern Time).

Presenting from the Company will be its Chief Executive Officer, Michael Castagna.

To participate in the live call by telephone, please dial (800) 263-0877 or (646) 828-8143 and use the participant passcode: 1338434. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at <http://www.mannkindcorp.com> under News & Events.

A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 or (412) 317-6671 and use the participant passcode: 1338434#. A replay will also be available on MannKind's website for 14 days.

### **About MannKind Corporation**

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza<sup>®</sup> (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S.

For further information, visit [www.mannkindcorp.com](http://www.mannkindcorp.com).

#### **Company Contact:**

Rose Alinaya  
SVP, Investor Relations  
818.661.5000  
[ir@mannkindcorp.com](mailto:ir@mannkindcorp.com)



Source: MannKind